Published: 2019-11-09

Acne & Rosacea

An Open-Label Extension of Two Phase 3 Studies Evaluating Long-Term Efficacy of FMX101 4% Minocycline Foam for the Treatment of Acne Vulgaris

Linda Stein Gold, Sunhil Dhawan, Jonathan Weiss, Zoe Diana Draelos, Herman Ellman, Iain Stuart
| DOI https://doi.org/10.25251/skin.3.supp.1

Page S1

Poster PDF

Clinical Safety and Pharmacokinetics of FMX101 4% Topical Minocycline Foam in Pediatric Patients for the Treatment of Moderate-to-Severe Acne Vulgaris

L Eichenfield, L Stein Gold, N Silverberg, T Raoof, D Hooper, A Moore, M Zaiac, T Sullivan, L Kircik, E Lain, S Dhawan, T Jones, J Weiss, Z Draelos, H Ellman, T deVries, J Jankicevic, I Stuart
| DOI https://doi.org/10.25251/skin.3.supp.2

Page S2

Poster PDF

Ex Vivo Assessment of FMX101 & FMX103 Human Skin Permeation and Penetration

Russell Elliott, Gary Lawrence, Yohan Hazot, Lenny Margulis, Vassilis Stakias, Iain Stuart
| DOI https://doi.org/10.25251/skin.3.supp.3

Page S3

Poster PDF

Real World Patient Perceptions of the use of Tazarotene 0.1% Foam in the Treatment of Acne Vulgaris

James Q Del Rosso, Corey L Hartman, Caitlin Lewis, Rhonda Schreiber
| DOI https://doi.org/10.25251/skin.3.supp.4

Page S4

Poster PDF

Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in an Asian Population

George Han, April W Armstrong, Seemal R Desai, Eric Guenin
| DOI https://doi.org/10.25251/skin.3.supp.5

Page S5

Poster PDF

A Randomized, Observer‑Blind, Split‑Face Study to Assess Compatibility of Facial Foundation Makeup with Tretinoin 0.05% Lotion and Skin Texture After Application

Neal Bhatia, Leon H Kircik, Ava Shamban, Varsha Bhatt, Radhakrishnan Pillai, Eric Guenin
| DOI https://doi.org/10.25251/skin.3.supp.6

Page S6

Poster PDF

Acne-Related Quality of Life: Efficacy of a Novel Tretinoin 0.05% Lotion in Male and Female Patients with Moderate-to-Severe Disease

Sharleen St. Surin-Lord, William Philip Werschler, Eric Guenin
| DOI https://doi.org/10.25251/skin.3.supp.7

Page S7

Poster PDF

Acne-Related Quality of Life: Correlation Between Acne Symptom Scores and Other Domains Following Treatment with Tretinoin 0.05% Lotion

Heather C Woolery-Lloyd, Julie C Harper, Eric Guenin
| DOI https://doi.org/10.25251/skin.3.supp.8

Page S8

Poster PDF

Comparison of a Novel Tazarotene 0.045% Lotion to Tazarotene 0.1% Cream: Patient-Reported Outcomes from a Phase 2 Clinical Trial

Zoe Draelos, Fran Cook-Bolden, Lawrence Green, Eric Guenin, Gina Martin, Radhakrishnan Pillai
| DOI https://doi.org/10.25251/skin.3.supp.9

Page S9

Poster PDF

DFD 29, a low dose oral minocycline, shows significant improvement in quality of life in subjects with papulopustular rosacea

Linda Stein Gold, Joshua Zeichner, Shanavas Alikunju, Anirudh Gautam, Srinivas Shenoy, Preeti Singh, Srinivas Sidgiddi
| DOI https://doi.org/10.25251/skin.3.supp.10

Page S10

Poster PDF

DFD-29, a low dose oral minocycline, demonstrates superior efficacy as compared to placebo and Oraycea ® Capsules (doxycycline HCl) in subjects with papulopustular rosacea

Athanasios Tsianakas, Neal Bhatia, Shanavas Alikunju, Anirudh Gautam, Srinivas Shenoy, Preeti Singh, Srinivas Sidgiddi
| DOI https://doi.org/10.25251/skin.3.supp.11

Page S11

Poster PDF

Poster Presentations from FC23 Dermatology Conference®: Psoriasis

An oral, selective tyrosine kinase 2 inhibitor, BMS-986165, improves quality of life in psoriasis: results from a Phase 2 study

D Thaci, K Papp, K Gordon, A Morita, M Gooderham, P Foley, E Alemano, R Kisa, Y Elbez, H Ren, S Banerjee
| DOI https://doi.org/10.25251/skin.3.supp.12

Page S12

Poster PDF

Lack of ECG effects of BMS-986165, an oral, selective tyrosine kinase 2 (TYK2) inhibitor: results from a thorough QT study in healthy subjects

IG Girgis, A Chimalakonda, JP Jones III, R Dockens, D Marchisin, R Darbenzio, S Singhal, J Throup, S Banerjee
| DOI https://doi.org/10.25251/skin.3.supp.13

Page S13

Poster PDF

Influence of baseline demographics/disease characteristics on efficacy of an oral selective TYK2 inhibitor, BMS-986165, in patients with moderate to severe plaque psoriasis: Phase 2, randomized, placebo-controlled trial

K Gordon, K Papp, M Gooderman, D Thaci, P Foley, A Morita, S Kundu, R Kisa, A Napoli, S Banerjee
| DOI https://doi.org/10.25251/skin.3.supp.14

Page S14

Poster PDF

Tapinarof Cream for the Treatment of Plaque Psoriasis: Efficacy and Safety by Baseline Disease Characteristics and Skin Type in a Phase 2b Randomized Study

Mark Lebwohl, James Del Rosso, Chih-ho Hong, Anna M Tallman, Leon Kircik
| DOI https://doi.org/10.25251/skin.3.supp.15

Page S15

Poster PDF

Secondary Efficacy Outcomes from a Phase 2b, Randomized Dose-Finding Study of Tapinarof Cream for the Treatment of Plaque Psoriasis

Linda Stein Gold, Neal Bhatia, Anna M Tallman, David Rubenstein
| DOI https://doi.org/10.25251/skin.3.supp.16

Page S16

Poster PDF

Maintenance of Response With up to 4 Years of Continuous Guselkumab Treatment: Results From the VOYAGE 1 Phase 3 Trial

C.E.M. Griffiths, K.A. Papp, M Song, M Miller, Y You, Y-K Shen, C Han, A Blauvelt
| DOI https://doi.org/10.25251/skin.3.supp.17

Page S17

Poster PDF

A multicenter, open label, Phase 1 study of the safety, tolerability, systemic exposure, pharmacodynamics, and treatment effect of calcipotriene foam, 0.005% in pediatric subjects (ages 2 to 11 years) with plaque psoriasis.

Adelaide A Herbert, Debbie Glaab, Rhonda Schreiber
| DOI https://doi.org/10.25251/skin.3.supp.18

Page S18

Poster PDF

Real World Patient Perceptions of the use of Calcipotriene Foam 0.005% in the Treatment of Plaque Psoriasis

Francisco Kerdel, Christina Don, Renata Block, Caitlin Lewis, Rhonda Schreiber
| DOI https://doi.org/10.25251/skin.3.supp.19

Page S19

Poster PDF

Patients With Psoriasis Treated With Brodalumab: A Pooled Post Hoc Analysis of a Marker of Liver Inflammation in Individuals With Potential Indicators of Early Nonalcoholic Fatty Liver Disease

Ronald Prussick, Mark Lebwohl, Nadege Gunn, Susan Harris, Jason Vittitow, Abby Jacobson, Robert J Israel
| DOI https://doi.org/10.25251/skin.3.supp.20

Page S20

Poster PDF

Long-term Efficacy and Safety of Brodalumab in Patients With or Without History of Psoriatic Arthritis: Analysis of Two Phase 3 Psoriasis Studies

Alice Gottlieb, Alan Menter, Paul Yamauchi, George Han, Radhakrishnan Pillai, Tina Lin, Abby Jacobson
| DOI https://doi.org/10.25251/skin.3.supp.21

Page S21

Poster PDF

Long-term Efficacy and Safety of Brodalumab in Patients With Psoriasis Whose Disease Did Not Respond to Prior Biologics

Mark Lebwohl, Lawrence Green, Miriam Bettencourt, Scott Fretzin, Abby Jacobson
| DOI https://doi.org/10.25251/skin.3.supp.22

Page S22

Poster PDF

Maintenance and Improvement of Skin Clearance Response With Brodalumab Among Patients With Moderate-to-Severe Psoriasis

Neal D Bhatia, Seemal R Desai, Craig Teller, Abby Jacobson
| DOI https://doi.org/10.25251/skin.3.supp.23

Page S23

Poster PDF

Importance of Complete Skin Clearance on Quality of Life: Analysis of Three Phase 3 Studies of Brodalumab

April Armstrong, Andrew Blauvelt, Scott Drew, Roger Ho, Abby Jacobson
| DOI https://doi.org/10.25251/skin.3.supp.24

Page S24

Poster PDF

Long-term Efficacy and Safety of Brodalumab in Patients With Psoriasis Disease Duration <10 and ≥10 Years: Analysis of Two Phase 3 Studies

Benjamin Ehst, George Han, Scott Guenthner, Kimberly Eads, Abby Jacobson
| DOI https://doi.org/10.25251/skin.3.supp.25

Page S25

Poster PDF

Long-term Efficacy, Safety, and Patient-Reported Outcomes in a Phase 2 Study of Brodalumab

Mark Lebwohl, Andrew Blauvelt, Alan Menter, Kim Papp, Abby Jacobson
| DOI https://doi.org/10.25251/skin.3.supp.26

Page S26

Poster PDF

Optimized Formulation for Topical Application of a Fixed Combination Halobetasol/Tazarotene Lotion Using Polymeric Emulsion Technology

Emil A Tanghetti, Linda Stein Gold, James Q Del Rosso, Stefan Weiss, Tina Lin, Arturo Angel, Radhakrishnan Pillai
| DOI https://doi.org/10.25251/skin.3.supp.27

Page S27

Poster PDF

Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Moderate-to-Severe Plaque Psoriasis in a Hispanic Population: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials

Andrew F Alexis, Paul S Yamauchi, Tina Lin, Gina Martin
| DOI https://doi.org/10.25251/skin.3.supp.28

Page S28

Poster PDF

Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Severe Plaque Psoriasis: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials

Mark G Lebwohl, Jeffrey L Sugarman, Linda Stein Gold, Tina Lin, Gina Martin
| DOI https://doi.org/10.25251/skin.3.supp.29

Page S29

Poster PDF

Efficacy of Halobetasol 0.01%/Tazarotene 0.045% (HP/TAZ) Fixed Combination in the Treatment of Moderate Plaque Psoriasis: Indirect Comparison Between Pooled Phase 3 Trials of HP/TAZ and Oral Treatment (Apremilast)

Brad Glick, Edward Lain, Tina Lin, Robert Israel
| DOI https://doi.org/10.25251/skin.3.supp.30

Page S30

Poster PDF

Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Fixed Combination Halobetasol Propionate 0.01% And Tazarotene 0.045% (HP/TAZ) Lotion

Lina Stein Gold, Mark G Lebwohl, Neal Bhatia, Tina Lin, Radhakrishnan Pillai
| DOI https://doi.org/10.25251/skin.3.supp.31

Page S31

Poster PDF

Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities

Neal Bhatia, Tracey C Vlahovic, Lawrence Green, Gina Martin, Tina Lin
| DOI https://doi.org/10.25251/skin.3.supp.32

Page S32

Poster PDF

PPC 06 ( Tepilamide Fumarate), a novel fumaric acid ester, is efficacious in treating plaque psoriasis: Results from a phase 2b randomized controlled trial

Mark Lebwohl, Leon Kircik, Kristian Reich, Sugar Munjal, Srinivas Shenoy, Ulrich Mrowietz
| DOI https://doi.org/10.25251/skin.3.supp.33

Page S33

Poster PDF

Bimekizumab provides rapid and sustained improvements in scalp and nail outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized, double blinded, Phase 2b extension study

Andrew Blauvelt, Kim A Papp, Joseph F Merola, Alice B Gottlieb, Nancy Cross, Cindy Madden, Luke Peterson, Christopher Cioffi, Christopher EM Griffiths
| DOI https://doi.org/10.25251/skin.3.supp.34

Page S34

Poster PDF

Bimekizumab provides rapid and sustained improvements in quality of life that correlate with clinical outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized , double blinded , Phase 2b extension study

Kim A Papp, Joseph F Merola, Alice B Gottlieb, Christopher EM Griffiths, Kristina K Harris, Nancy Cross, Luke Peterson, Christopher Cioffi, Andrew Blauvelt
| DOI https://doi.org/10.25251/skin.3.supp.35

Page S35

Poster PDF

Long-Term Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks in Patients with Plaque Psoriasis: Pooled 128-Week Data from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)

K Gordon, R.B. Warren, A.B. Gottlieb, A Blauvelt, D Thaci, C Leonardi, Y Poulin, M Boehnlein, S Kavanagh, C Arendt, K Reich
| DOI https://doi.org/10.25251/skin.3.supp.36

Page S36

Poster PDF

Certolizumab Pegol for Treatment of Plaque Psoriasis: Pooled Three-Year Efficacy Outcomes from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)

K Gordon, R.B. Warren, A.B. Gottlieb, A. Blauvelt, D Thaci, C Leonardi, Y Poulin, M Boehnlein, S Kavanagh, C Arendt, K Reich
| DOI https://doi.org/10.25251/skin.3.supp.37

Page S37

Poster PDF

Nail Outcome Improvements with Certolizumab Pegol in Moderate to Severe Plaque Psoriasis: Results from Phase 3 Trials

A.B. Gottlieb, D Thaci, C Leonardi, Y Poulin, S Kavanagh, M Boehnlein, K Reich
| DOI https://doi.org/10.25251/skin.3.supp.38

Page S38

Poster PDF

Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled 96-Week Data from Three Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT)

A Blauvelt, B Strober, R Langley, S Kavanagh, C Arendt, M Boehnlein, M Lebwohl, K Reich
| DOI https://doi.org/10.25251/skin.3.supp.39

Page S39

Poster PDF

Efficacy of Certolizumab Pegol for Psoriasis of the Head and Neck in Two Phase 3 Clinical Trials: CIMPASI-1 and CIMPASI-2

P van de Kerkhof, A Pinter, M Boehnlein, S Kavanagh, J.J. Crowley
| DOI https://doi.org/10.25251/skin.3.supp.40

Page S40

Poster PDF

Eczema & Xerosis

Lebrikizumab, a High-Affinity IL-13 Inhibitor, Improves Clinical Manifestations in Moderate-to-Severe Atopic Dermatitis: Primary Results From a Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Phase 2b Study

E Guttman-Yassky, A Blauvelt, L.F. Eichenfield, A Paller, A Armstrong, J Drew, R Gopalan, E Simpson
| DOI https://doi.org/10.25251/skin.3.supp.41

Page S41

Poster PDF

Atopic dermatitis disease biomarkers strongly correlate with IL-13 levels, are regulated by IL-13, and are modulated by tralokinumab in vitro

Stephan Weidinger, Maxim A.X. Tollenaere, Katharina Drerup, Thomas Litman, Hanne Norsgaard
| DOI https://doi.org/10.25251/skin.3.supp.42

Page S42

Poster PDF

The Low Prevalence of Allergic Contact Dermatitis Using a Petrolatum Ointment Containing Lanolin Alcohol

| DOI https://doi.org/10.25251/skin.3.supp.43

Page S43

Poster PDF

A Comparison of Efficacy among Therapeutic Moisturizing Creams

CE Arrowitz, LI Jiang, PD Hino, MJ Babcock, TM Weber
| DOI https://doi.org/10.25251/skin.3.supp.44

Page S44

Poster PDF

A 14 Day, Single Blind, Controlled Study to Assess the Qualitative Improvement in Skin Moisturization and Desquamation of 15% Lactic Acid Moisturizer with Ceramides (LAMC) Treatment in Healthy Female Subjects

Zoe Diane Draelos, Steven B Hall, Carey Munsick
| DOI https://doi.org/10.25251/skin.3.supp.45

Page S45

Poster PDF

Skin Cancer

Safety of Large Field (>20cm2) Photodynamic Therapy Using 10% Aminolevulinic Acid Hydrochloride Nanoemulsion Gel Comparing Blue to Red Light Illumination

Angela Yen Moore, Stephen Moore
| DOI https://doi.org/10.25251/skin.3.supp.46

Page S46

Poster PDF

Photodynamic therapy with BF-200 ALA for the treatment of mild to severe actinic keratosis on extremities and trunk/neck: Results of a randomized Phase III trial

T Dirschka, M Ulrich, U Reinhold, R Dominicus, R Aschoff, R.M. Szeimies
| DOI https://doi.org/10.25251/skin.3.supp.47

Page S47

Poster PDF

A randomized, double blind, vehicle-controlled multicenter phase III study to evaluate the safety and efficacy of BF-200 ALA and narrowband red light in the treatment of superficial basal cell carcinoma (sBCC) with photodynamic therapy (PDT)

V Laquer, S Bruce, T Schlesinger, N Zeitouni, A Torres, J Cohen, J Tu, W Hanke, M Goldman, D Ozog, O Markowitz, M Gold, M Nestor, B Berman, G Munavalli, D Pariser
| DOI https://doi.org/10.25251/skin.3.supp.48

Page S48

Poster PDF

Follow-up results of a randomized, double-blind, phase III, multi-center study to evaluate the safety and efficacy of BF-200 ALA versus placebo in field-directed treatment of mild to moderate AK with photodynamic therapy when using narrowband red light

U Reinhold, T Dirschka, R Ostendorf, R Aschoff, C Berking, W Philipp-Dormston, R.M. Szeimies
| DOI https://doi.org/10.25251/skin.3.supp.49

Page S49

Poster PDF

Multidisciplinary Expert-Driven Consensus on the Evolving Treatment of Patients with Advanced Cutaneous Squamous Cell Carcinoma

Michael R Migden, Todd E Schlesinger, Chrysalyne D Schmults, Scott M Dinehart, Robert L Ferris, Morganna Freeman, Valerie Guild, Shlomo Koyfman, Anna C Pavlick, Gregory T Wolf, Guilherme Rabinowits, Neil Swanson
| DOI https://doi.org/10.25251/skin.3.supp.50

Page S50

Poster PDF

Recurrence prediction in cutaneous melanoma with 31-gene expression profiling and sentinel lymph node biopsy

Graham Litchman, Hilary Caruso, Robert Cook, Darrell Rigel
| DOI https://doi.org/10.25251/skin.3.supp.51

Page S51

Poster PDF

Findings from a large US registry study to assess the real-world utility of a non-invasive gene expression test designed to rule out primary cutaneous melanoma

Brook Brouha, Laura K Ferris, Maral K Skelsey, Gary Peck, Zuxu Yao, Burkhard Jansen
| DOI https://doi.org/10.25251/skin.3.supp.52

Page S52

Poster PDF

Association Between Baseline Disease Characteristics and Relapse-Free Survival in Patients With BRAF V600–Mutant Resected Stage III Melanoma Treated With Adjuvant Dabrafenib + Trametinib or Placebo

Dirk Schadendorf, Reinhard Dummer, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandala, Vanna Chiarion-Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux, Andrew Haydon, Laurent Mortier, Caroline Robert, Jacob Schachter, Christine-Elke Ortmann, Egbert de Jong, Edward Gasal, Richard Kefford, John M Kirkwood, Georgina V Long
| DOI https://doi.org/10.25251/skin.3.supp.53

Page S53

Poster PDF

Hyperhidrosis

A Multi-Center, Open-Label Study to Assess Pharmacokinetics (PK), Safety and Tolerability of Sofpironium Bromide Gel, 15% Applied Topically to Children and Adolescents, ≥9 to <17 Years of Age, with Axillary Hyperhidrosis

Brandon Kirsch, Janet DuBois, Deepak Chadha
| DOI https://doi.org/10.25251/skin.3.supp.54

Page S54

Poster PDF

Limited Systemic Exposure with Topical Glycopyrronium Tosylate across Multiple Studies in Healthy Volunteers and Patients with Primary Axillary Hyperhidrosis

D.M. Pariser, E.L. Lain, R Mamelok, J Drew, D.R. Mould
| DOI https://doi.org/10.25251/skin.3.supp.55

Page S55

Poster PDF

Dermatopharmacology

Measuring the Predictive Value of Serological Quantification of Cytokines with the Onset of Influenza-Like Signs and Symptoms Induced by Imiquimod 3.75% Cream: Results of a Single Center, Open-Label, Proof of Concept Trial

Neal Bhatia
| DOI https://doi.org/10.25251/skin.3.supp.56

Page S56

Poster PDF

Comparative Pharmacokinetic Profiles of a Novel Low-Dose Micronized-Isotretinoin 32-mg Formulation and Lidose-Isotretinoin 40 mg in Fed and Fasted Conditions: 2 Open-label, Randomized Crossover Studies in Healthy Adult Participants

Sumit Madan, Sudershan Kumar, Jeanett Segal
| DOI https://doi.org/10.25251/skin.3.supp.57

Page S57

Poster PDF